ΔNp73/ETS2复合物驱动胶质母细胞瘤发病机制——用瑞巴替尼靶向下游介质可延长临床前胶质母细胞瘤模型生存期
该研究探讨ΔNp73通过ETS2上调ANGPT1/Tie2轴的生物学效应,并在胶质瘤球培养、异种移植瘤及患者标本中验证。在斑马鱼和小鼠颅内注射模型中,ΔNp73高表达促进血管生成和生存;口服小分子抑制剂瑞巴替尼靶向下游信号,抑制已建立肿瘤生长并延长生存。
要点
- ΔNp73通过ETS保守结合位点与ETS2相互作用,转录上调ANGPT1和Tie2。
- ΔNp73高表达通过介导血管生成和生存促进肿瘤进展。
- 瑞巴替尼靶向下游ΔNp73信号,抑制已建立肿瘤生长并延长临床前模型生存。
核心结论
- 胶质母细胞瘤中ΔNp73的异常表达通过依赖ANGPT1激活Tie2的自分泌和旁分泌信号促进肿瘤进展。
- 瑞巴替尼破坏该信号可改善胶质母细胞瘤的治疗反应。
研究设计与样本
- 在胶质瘤球培养、异种移植胶质母细胞瘤肿瘤和胶质母细胞瘤患者中,用蛋白质印迹、定量逆转录PCR和免疫组化评估ΔNp73表达。
- 用免疫沉淀、染色质免疫沉淀(ChIP)和连续ChIP确定ΔNp73与E26转化特异性原癌基因2(ETS2)蛋白的相互作用。
- 用体外和体内实验(包括原位斑马鱼和小鼠颅内注射模型)检查ΔNp73在胶质母细胞瘤中的致癌后果。
- 在颅内注射小鼠模型中检查瑞巴替尼对已建立肿瘤生长和生存的影响。
主要发现
- ΔNp73通过与ETS2相互作用,经启动子上的ETS保守结合位点转录上调ANGPT1和Tie2。
- ΔNp73高表达通过介导血管生成和生存促进肿瘤进展。
- 用瑞巴替尼靶向下游ΔNp73信号通路可抑制已建立肿瘤生长并延长胶质母细胞瘤临床前模型生存。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma (GBM) remains one of the least successfully treated cancers. It is essential to understand the basic biology of this lethal disease and investigate novel pharmacological targets to treat GBM. The aims of this study were to determine the biological consequences of elevated expression of ΔNp73, an N-terminal truncated isoform of TP73, and to evaluate targeting of its downstream mediators, the angiopoietin 1 (ANGPT1)/tunica interna endothelial cell kinase 2 (Tie2) axis, by using a highly potent, orally available small-molecule inhibitor (rebastinib) in GBM. METHODS: ΔNp73 expression was assessed in glioma sphere cultures, xenograft glioblastoma tumors, and glioblastoma patients by western blot, quantitative reverse transcription PCR, and immunohistochemistry. Immunoprecipitation, chromatin immunoprecipitation (ChiP) and sequential ChIP were performed to determine the interaction between ΔNp73 and E26 transformation-specific (ETS) proto-oncogene 2 (ETS2) proteins. The oncogenic consequences of ΔNp73 expression in glioblastomas were examined by in vitro and in vivo experiments, including orthotopic zebrafish and mouse intracranial-injection models. Effects of rebastinib on growth of established tumors and survival were examined in an intracranial-injection mouse model. RESULTS: ΔNp73 upregulates both ANGPT1 and Tie2 transcriptionally through ETS conserved binding sites on the promoters by interacting with ETS2. Elevated expression of ΔNp73 promotes tumor progression by mediating angiogenesis and survival. Therapeutic targeting of downstream ΔNp73 signaling pathways by rebastinib inhibits growth of established tumors and extends survival in preclinical models of glioblastoma. CONCLUSION: Aberrant expression of ΔNp73 in GBM promotes tumor progression through autocrine and paracrine signaling dependent on Tie2 activation by ANGPT1. Disruption of this signaling by rebastinib improves tumor response to treatment in glioblastoma.
引用
- Cam M, Charan M, Welker AM, et al. ΔNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma. Neuro Oncol. 2020. PMID: 31763674. doi:10.1093/neuonc/noz190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。